Condition: Small Cell Lung Cancer · Renal Cell Carcinoma (RCC) · Non-Small Cell Lung · Sponsor: Advenchen Pharmaceuticals, LLC.
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
This description comes directly from the study's public registry record.
Shiying Sprinzl · 805-530-1550 · shiyings@advenchen.com
Judy Chen · 805-530-1550 · Judyc@advenchen.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Cleveland Clinic Florida | Weston, Florida, United States | Withdrawn |
| Northwestern University | Chicago, Illinois, United States | Completed |
| Siteman Cancer Center, Washington University | St Louis, Missouri, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Hospital Universitario Ramón Y Cajal | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05363280